GFAP and myeloid sarcoma: Furthermore, protein products that are released from dying astrocytes such as GFAP and chitinase-3-like protein 1 (C3L1) are detected at increased levels in the CSF and serum of MS and are prognostic biomarkers for disease progression (173–175).